OpenLB
Open Library of Bioscience
Advanced Search
Current opinion in infectious diseases
Dec 01, 2024;37 (6): 582-588.

New antibiotics in clinical pipeline for treating infections caused by metallo-��-lactamases producing Gram-negative bacteria.

Matteo Bassetti, Antonio Vena, Barbara Larosa, Daniele Roberto Giacobbe
Author Information
  1. Matteo Bassetti: Department of Health Sciences (DISSAL), University of Genoa.
  2. Antonio Vena: Department of Health Sciences (DISSAL), University of Genoa.
  3. Barbara Larosa: Department of Health Sciences (DISSAL), University of Genoa.
  4. Daniele Roberto Giacobbe: Department of Health Sciences (DISSAL), University of Genoa.
PMID: 39106036 DOI: 10.1097/QCO.0000000000001056

Abstract

PURPOSE OF REVIEW: To discuss novel antibiotics under clinical development, focusing on agents showing in-vitro activity against metallo-��-lactamases (MBL)-producing carbapenem-resistant Gram-negative bacteria (CR-GNB).
RECENT FINDINGS: Currently, only a few approved agents show activity, alone or in synergistic combinations, against MBL-producing CR-GNB. If approved by regulatory agencies in case of favorable results from ongoing (and, for some agents, already completed) phase-3 studies, some novel ��-lactam/��-lactamase inhibitor (BL/BLI) combinations could become available in the next few years as additional important options for treating MBL-producing CR-GNB infections. Additional interesting agents that belong both to BL/BLI combinations and to antibiotic classes other than BL and BL/BLI combinations have also shown activity against MBL-producing CR-GNB, with most of them being in early phases of clinical development.
SUMMARY: Improving the use of these novel agents through virtuous antimicrobial stewardship frameworks able to guarantee both the efficacious treatment of infections requiring their use and the avoidance of their use whenever not necessary remains a challenge of utmost importance that should not be overlooked.

References

  1. Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum beta-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2022; 75:187���212.
  2. Paul M, Carrara E, Retamar P, et al. European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine). Clin Microbiol Infect 2022; 28:521���547.
  3. Tsuji BT, Pogue JM, Zavascki AP, et al. International Consensus Guidelines for the Optimal Use of the Polymyxins: Endorsed by the American College of Clinical Pharmacy (ACCP), European Society of Clinical Microbiology and Infectious Diseases (ESCMID), Infectious Diseases Society of America (IDSA), International Society for Antiinfective Pharmacology (ISAP), Society of Critical Care Medicine (SCCM), and Society of Infectious Diseases Pharmacists (SIDP). Pharmacotherapy 2019; 39:10���39.
  4. Karaiskos I, Galani I, Souli M, Giamarellou H. Novel beta-lactam-beta-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens. Expert Opin Drug Metab Toxicol 2019; 15:133���149.
  5. Giacobbe DR, Di Pilato V, Karaiskos I, et al. Treatment and diagnosis of severe KPC-producing Klebsiella pneumoniae infections: a perspective on what has changed over last decades. Ann Med 2023; 55:101���113.
  6. Bassetti M, Di Pilato V, Giani T, et al. Treatment of severe infections due to metallo-beta-lactamases-producing Gram-negative bacteria. Future Microbiol 2020; 15:1489���1505.
  7. Mushtaq S, Vickers A, Doumith M, et al. Activity of beta-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria. J Antimicrob Chemother 2021; 76:160���170.
  8. Hamrick JC, Docquier JD, Uehara T, et al. VNRX-5133 (Taniborbactam), a broad-spectrum inhibitor of serine- and metallo-beta-Lactamases, restores activity of cefepime in enterobacterales and Pseudomonas aeruginosa. Antimicrob Agents Chemother 2020; 64:e01963���e01919.
  9. Venatorx Pharmaceuticals. Venatorx and Melinta provide update on status of U.S. New Drug Application for Cefepime-Taniborbactam. https://venatorx.com/press-releases/venatorx-and-melinta-provide-update-on-status-of-u-s-new-drug-application-for-cefepime-taniborbactam/ . [Accessed 27 June 2024]
  10. Wagenlehner FM, Gasink LB, McGovern PC, et al. Cefepime-taniborbactam in complicated urinary tract infection. N Engl J Med 2024; 390:611���622.
  11. Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP (CERTAIN-2). https://clinicaltrials.gov/study/NCT06168734 . [Accessed 27 June 2024.]
  12. Yahav D, Giske CG, Gramatniece A, et al. New beta-lactam-beta-lactamase inhibitor combinations. Clin Microbiol Rev 2020; 34:e00115���e00120.
  13. Sader HS, Mendes RE, Pfaller MA, et al. Antimicrobial activities of aztreonam-avibactam and comparator agents against contemporary (2016) clinical Enterobacteriaceae isolates. Antimicrob Agents Chemother 2018; 62:e01856-17.
  14. Pfizer Press Release. European Commission approves Pfizer's EMBLAVEO�� for patients with multidrug-resistant infections and limited treatment options. https://www.pfizer.com/news/press-release/press-release-detail/european-commission-approves-pfizers-emblaveor-patients . [Accessed 27 June 2024]
  15. Carmeli Y, Cisneros J-M, Paul M, et al. 2893 A efficacy and safety of aztreonam-avibactam for the treatment of serious infections due to Gram-negative bacteria, including metallo-��-Lactamase-producing pathogens: Phase 3 REVISIT Study. Open Forum Infect Dis 2023; 10:ofad500.2476.
  16. NCT03329092. A study to determine the efficacy, safety and tolerability of Aztreonam-Avibactam (ATM-AVI)��������Metronidazole (MTZ) Versus Meropenem (MER)��������Colistin (COL) for the Treatment of Serious Infections Due to Gram Negative Bacteria. (REVISIT). https://classic.clinicaltrials.gov/ct2/show/results/NCT03329092 . [Accessed 27 June 2024]
  17. NCT03580044. Efficacy, safety, and tolerability of ATM-AVI in the treatment of serious infection due to MBL-producing Gram-negative bacteria. https://classic.clinicaltrials.gov/ct2/show/results/NCT03580044 . [Accessed 27 June 2024]
  18. NCT05887908. Efficacy and Safety of Cefepime/Nacubactam or Aztreonam/Nacubactam Compared to Imipenem/Cilastatin in Subjects With Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis (Integral-1). https://clinicaltrials.gov/study/NCT05887908 . [Accessed 27 June 2024]
  19. NCT05905055. P3 Study to Assess Efficacy and Safety of Cefepime/Nacubactam and Aztreonam/Nacubactam Versus Best Available Therapy for Adults With Infection Due to Carbapenem Resistant Enterobacterales (Integral-2). https://clinicaltrials.gov/study/NCT05905055 . [Accessed 27 June 2024]
  20. Morinaka A, Tsutsumi Y, Yamada M, et al. OP0595, a new diazabicyclooctane: mode of action as a serine beta-lactamase inhibitor, antibiotic and beta-lactam ���enhancer���. J Antimicrob Chemother 2015; 70:2779���2786.
  21. Paterson DL. Antibacterial agents active against Gram negative bacilli in phase I, II, or III clinical trials. Expert Opin Investig Drugs 2024; 33:371���387.
  22. Livermore DM, Mushtaq S, Warner M, Woodford N. Activity of OP0595/beta-lactam combinations against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing beta-lactamases. J Antimicrob Chemother 2015; 70:3032���3041.
  23. Moya B, Bhagwat S, Cabot G, et al. Effective inhibition of PBPs by cefepime and zidebactam in the presence of VIM-1 drives potent bactericidal activity against MBL-expressing Pseudomonas aeruginosa. J Antimicrob Chemother 2020; 75:1474���1478.
  24. Livermore DM, Mushtaq S, Warner M, et al. In vitro activity of cefepime/zidebactam (WCK 5222) against Gram-negative bacteria. J Antimicrob Chemother 2017; 72:1373���1385.
  25. NCT04979806. Study of Cefepime-zidebactam (FEP-ZID) in Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP). https://clinicaltrials.gov/study/NCT04979806 . [Accessed 27 June 2024]
  26. Tirlangi PK, Wanve BS, Dubbudu RR, et al. Successful use of cefepime-zidebactam (WCK 5222) as a salvage therapy for the treatment of disseminated extensively drug-resistant New Delhi metallo-beta-lactamase-producing Pseudomonas aeruginosa infection in an adult patient with acute T-cell leukemia. Antimicrob Agents Chemother 2023; 67:e0050023.
  27. Soman R, Sirsat R, Sunavala A, et al. Successful treatment of sino-pulmonary infection & skull base osteomyelitis caused by New Delhi metallo-beta-lactamase-producing Pseudomonas aeruginosa in a renal transplant recipient by using an investigational antibiotic cefepime/zidebactam (WCK 5222). Eur J Clin Microbiol Infect Dis 2024; doi: 10.1007/s10096-024-04791-1. [DOI: 10.1007/s10096-024-04791-1]
  28. Dubey D, Roy M, Shah TH, et al. Compassionate use of a novel beta-lactam enhancer-based investigational antibiotic cefepime/zidebactam (WCK 5222) for the treatment of extensively-drug-resistant NDM-expressing Pseudomonas aeruginosa infection in an intra-abdominal infection-induced sepsis patient: a case report. Ann Clin Microbiol Antimicrob 2023; 22:55.
  29. Asempa TE, Motos A, Abdelraouf K, et al. Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model. Int J Antimicrob Agents 2020; 55:105838.
  30. World Health Organization. 2023 Antibacterial agents in clinical and preclinical development: an overview and analysis https://www.who.int/publications/i/item/9789240094000 . [Accessed 27 June 2024]
  31. Sumitomo Pharma. Kitasato Institute and Sumitomo Dainippon Pharma Start Phase 1 Study on New Drug Candidate Compound Discovered in Joint Research as Treatment for Carbapenem-resistant Bacterial Infections. https://www.sumitomo-pharma.com/news/20220113.html . [Accessed 27 June 2024]
  32. Mushtaq S, Vickers A, Chaudhry A, et al. Inoculum effects of cefepime/zidebactam (WCK 5222) and ertapenem/zidebactam (WCK 6777) for Enterobacterales in relation to beta-lactamase type and enhancer effect, as tested by BSAC agar dilution. J Antimicrob Chemother 2022; 77:1916���1922.
  33. Gethers M, Chen I, Abdelraouf K, Nicolau DP. In vivo efficacy of WCK 6777���(ertapenem/zidebactam) against carbapenemase-producing Klebsiella pneumoniae in the neutropenic murine pneumonia model. J Antimicrob Chemother 2022; 77:1931���1937.
  34. Sun D, Tsivkovski R, Pogliano J, et al. Intrinsic antibacterial activity of Xeruborbactam in vitro: assessing spectrum and mode of action. Antimicrob Agents Chemother 2022; 66:e0087922.
  35. Nelson K, Rubio-Aparicio D, Sun D, et al. In vitro activity of the ultrabroad-spectrum-beta-lactamase inhibitor QPX7728 against carbapenem-resistant enterobacterales with varying intrinsic and acquired resistance mechanisms. Antimicrob Agents Chemother 2020; 64:
  36. Lomovskaya O, Tsivkovski R, Sun D, et al. QPX7728, an ultra-broad-spectrum B-lactamase inhibitor for intravenous and oral therapy: overview of biochemical and microbiological characteristics. Front Microbiol 2021; 12:697180.
  37. Lomovskaya O, Tsivkovski R, Nelson K, et al. Spectrum of beta-lactamase inhibition by the cyclic boronate QPX7728, an ultrabroad-spectrum beta-lactamase inhibitor of serine and metallo-beta-lactamases: enhancement of activity of multiple antibiotics against isogenic strains expressing single beta-lactamases. Antimicrob Agents Chemother 2020; 64:e00212-20.
  38. Lomovskaya O, Rubio-Aparicio D, Tsivkovski R, et al. The ultrabroad-spectrum beta-lactamase inhibitor QPX7728 restores the potency of multiple oral beta-lactam antibiotics against beta-lactamase-producing strains of resistant enterobacterales. Antimicrob Agents Chemother 2022; 66:e0216821.
  39. Shionogi & Co., Ltd. Qpex Biopharma, a Shionogi Group Company, Receives an Additional $10���M Award by BARDA as Part of Qpex's Partnership to Advance its Portfolio of Antibiotics Addressing Drug-Resistant Infections. https://www.shionogi.com/global/en/news/2024/05/E_20240531_1.html . [Accessed 7 July 2024]
  40. Giacobbe DR, Saffioti C, Losito AR, et al. Use of colistin in adult patients: a cross-sectional study. J Glob Antimicrob Resist 2020; 20:43���49.
  41. Pogue JM, Ortwine JK, Kaye KS. Clinical considerations for optimal use of the polymyxins: a focus on agent selection and dosing. Clin Microbiol Infect 2017; 23:229���233.
  42. Nation RL, Forrest A. Clinical pharmacokinetics, pharmacodynamics and toxicodynamics of polymyxins: implications for therapeutic use. Adv Exp Med Biol 2019; 1145:219���249.
  43. Giacobbe DR, Karaiskos I, Bassetti M. How do we optimize the prescribing of intravenous polymyxins to increase their longevity and efficacy in critically ill patients? Expert Opin Pharmacother 2022; 23:5���8.
  44. Zhang Y, Zhao C, Wang Q, et al. Evaluation of the in vitro activity of new polymyxin B analogue SPR206 against clinical MDR, colistin-resistant and tigecycline-resistant Gram-negative bacilli. J Antimicrob Chemother 2020; 75:2609���2615.
  45. Roberts KD, Zhu Y, Azad MAK, et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat Commun 2022; 13:1625.
  46. Duncan LR, Wang W, Sader HS. In vitro potency and spectrum of the novel Polymyxin MRX-8 tested against clinical isolates of Gram-negative bacteria. Antimicrob Agents Chemother 2022; 66:e0013922.
  47. Zhao C, Chirkova A, Rosenborg S, et al. Population pharmacokinetics of apramycin from first-in-human plasma and urine data to support prediction of efficacious dose. J Antimicrob Chemother 2022; 77:2718���2728.
  48. Hao M, Shi X, Lv J, et al. In vitro activity of apramycin against carbapenem-resistant and hypervirulent Klebsiella pneumoniae isolates. Front Microbiol 2020; 11:425.
  49. Huband MD, Mendes RE, Pfaller MA, et al. In Vitro Activity of KBP-7072, a novel third-generation tetracycline, against 531 recent geographically diverse and molecularly characterized Acinetobacter baumannii species complex isolates. Antimicrob Agents Chemother 2020; 64:
  50. Han R, Ding L, Yang Y, et al. In vitro activity of KBP-7072 against 536 Acinetobacter baumannii complex isolates collected in China. Microbiol Spectr 2022; 10:e0147121.
  51. Pfaller MA, Li L, Liu Q, et al. In vitro activity of a novel aminomethylcycline antibacterial (KBP-7072), a third-generation tetracycline, against clinical isolates with molecularly characterized tetracycline resistance mechanisms. JAC Antimicrob Resist 2021; 3:dlab177.
  52. Michaeli J, Mandel S, Maximov S, et al. In vitro and in vivo antimicrobial activity of the novel peptide OMN6 against multidrug-resistant Acinetobacter baumannii. Antibiotics (Basel) 2022; 11:
  53. Mandel S, Michaeli J, Nur N, et al. OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram negative bacteria. Sci Rep 2021; 11:6603.
  54. Werneburg M, Zerbe K, Juhas M, et al. Inhibition of lipopolysaccharide transport to the outer membrane in Pseudomonas aeruginosa by peptidomimetic antibiotics. Chembiochem 2012; 13:1767���1775.
  55. Wang Y, Chang RYK, Britton WJ, Chan HK. Advances in the development of antimicrobial peptides and proteins for inhaled therapy. Adv Drug Deliv Rev 2022; 180:114066.
  56. Srinivas N, Jetter P, Ueberbacher BJ, et al. Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa. Science 2010; 327:1010���1013.
  57. Sader HS, Flamm RK, Dale GE, et al. Murepavadin activity tested against contemporary (2016-17) clinical isolates of XDR Pseudomonas aeruginosa. J Antimicrob Chemother 2018; 73:2400���2404.
  58. Giacobbe DR, Ciacco E, Girmenia C, et al. Evaluating cefiderocol in the treatment of multidrug-resistant Gram-negative bacilli: a review of the emerging data. Infect Drug Resist 2020; 13:4697���4711.
  59. Falcone M, Daikos GL, Tiseo G, et al. Efficacy of ceftazidime-avibactam plus aztreonam in patients with bloodstream infections caused by metallo-beta-lactamase-producing enterobacterales. Clin Infect Dis 2021; 72:1871���1878.

MeSH Term

Humans
Gram-Negative Bacterial Infections
Anti-Bacterial Agents
Gram-Negative Bacteria
beta-Lactamases
beta-Lactamase Inhibitors
Microbial Sensitivity Tests

Chemicals

Anti-Bacterial Agents
beta-Lactamases
beta-Lactamase Inhibitors
Journal Article Review

Word Cloud

Created with Highcharts 10.0.0agentsCR-GNBcombinationsnovelclinicalactivityMBL-producingBL/BLIinfectionsuseantibioticsdevelopmentmetallo-��-lactamasesGram-negativebacteriaapprovedtreatingPURPOSEOFREVIEW:discussfocusingshowingin-vitroMBL-producingcarbapenem-resistantRECENTFINDINGS:Currentlyshowalonesynergisticregulatoryagenciescasefavorableresultsongoingalreadycompletedphase-3studies��-lactam/��-lactamaseinhibitorbecomeavailablenextyearsadditionalimportantoptionsAdditionalinterestingbelongantibioticclassesBLalsoshownearlyphasesSUMMARY:ImprovingvirtuousantimicrobialstewardshipframeworksableguaranteeefficacioustreatmentrequiringavoidancewhenevernecessaryremainschallengeutmostimportanceoverlookedNewpipelinecausedproducing

Similar Articles

Cited By